These findings indicate that the therapeutic effects of miR‐32533 on AD‐related pathologies, including cognitive impairment, neurodegeneration, Aβ generation, oxidation, and inflammation, may depend on CREB5. Here, CREB5 is linked to Alzheimer disease.